Date: 2011-10-17
Type of information: Collaboration agreement
Compound: oligonucleotide microarrays and SureSelect target enrichment products for next-generation sequencing
Company: Agilent Technologies (USA) Oxford Gene Technology (UK)
Therapeutic area:
Type agreement:
Action mechanism:
Disease:
Details: * On October 17, 2011, Agilent Technologies and Oxford Gene Technology have announced they have expanded an existing partnership into an exclusive agreement for Agilent to provide OGT with oligonucleotide microarrays and SureSelect target enrichment products for next-generation sequencing.The initial agreement, announced in 2007, gave OGT access to Agilent’s microarray platform and appointed it an Agilent Certified Service Provider for microarrays. In 2010, following the successful completion of the world’s largest copy number variation study, OGT was the first company to be awarded Agilent High-Throughput Microarray Certified Service Provider status.
The Agilent SureSelect Target Enrichment System is an in-solution hybridization capture technology first developed in collaboration with the Broad Institute of MIT and Harvard University, and subsequently published in Nature Biotechnology. The technology streamlines next-generation sequencing by helping to enable researchers to sequence only genomic regions of interest. One hundred twenty-mer RNA oligos provide reliable capture of more small and large variants, including SNPs, CNVs and Indels with unsurpassed allelic balance.
Financial terms:
Latest news:
